Literature DB >> 22399488

Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth.

Zongqing Tan1, Matthew Wortman, Kelsey L Dillehay, William L Seibel, Chris R Evelyn, Shanna J Smith, Linda H Malkas, Yi Zheng, Shan Lu, Zhongyun Dong.   

Abstract

Proliferating cell nuclear antigen (PCNA), a potential anticancer target, forms a homotrimer and is required for DNA replication and numerous other cellular processes. The purpose of this study was to identify novel small molecules that modulate PCNA activity to affect tumor cell proliferation. An in silico screen of a compound library against a crystal structure of PCNA and a subsequent structural similarity search of the ZINC chemical database were carried out to derive relevant docking partners. Nine compounds, termed PCNA inhibitors (PCNA-Is), were selected for further characterization. PCNA-I1 selectively bound to PCNA trimers with a dissociation constant (K(d)) of ~0.2 to 0.4 μM. PCNA-Is promoted the formation of SDS-refractory PCNA trimers. PCNA-I1 dose- and time-dependently reduced the chromatin-associated PCNA in cells. Consistent with its effects on PCNA trimer stabilization, PCNA-I1 inhibited the growth of tumor cells of various tissue types with an IC(50) of ~0.2 μM, whereas it affected the growth of nontransformed cells at significantly higher concentrations (IC(50), ~1.6 μM). Moreover, uptake of BrdU was dose-dependently reduced in cells treated with PCNA-I1. Mechanistically the PCNA-Is mimicked the effect of PCNA knockdown by siRNA, inducing cancer cell arrest at both the S and G(2)/M phases. Thus, we have identified a class of compounds that can directly bind to PCNA, stabilize PCNA trimers, reduce PCNA association with chromatin, and inhibit tumor cell growth by inducing a cell cycle arrest. They are valuable tools in studying PCNA function and may be useful for future PCNA-targeted cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399488      PMCID: PMC3362894          DOI: 10.1124/mol.112.077735

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  48 in total

Review 1.  The DNA replication fork in eukaryotic cells.

Authors:  S Waga; B Stillman
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

2.  Clinical validity of proliferating cell nuclear antigen as an objective marker for evaluating biologic features in patients with untreated prostate cancer.

Authors:  Shigehito Miyamoto; Kazuto Ito; Kohei Kurokawa; Kazuhiro Suzuki; Keiji Suzuki; Hidetoshi Yamanaka
Journal:  Int J Urol       Date:  2006-06       Impact factor: 3.369

Review 3.  Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps.

Authors:  Z Kelman; M O'Donnell
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

4.  Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA.

Authors:  J M Gulbis; Z Kelman; J Hurwitz; M O'Donnell; J Kuriyan
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

5.  [In vitro experiment of inhibiting cell proliferation on human esophageal squamous cell cancer T. Tn cell line by proliferating cell nuclear antigen antisense oligodeoxynucleotide].

Authors:  Lin Yang; Shi-duo Ye; Lun-gao Feng; Jia-shun Wang; Wei Zhai
Journal:  Ai Zheng       Date:  2002-03

Review 6.  Molecular and histological markers in urothelial carcinomas of the upper urinary tract.

Authors:  Stephanie Eltz; Eva Comperat; Olivier Cussenot; Morgan Rouprêt
Journal:  BJU Int       Date:  2008-04-02       Impact factor: 5.588

7.  Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins.

Authors:  J M Almendral; D Huebsch; P A Blundell; H Macdonald-Bravo; R Bravo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

8.  Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.

Authors:  WeiDe Zhong; Jinyu Peng; HuiChan He; Dinglan Wu; ZhaoDong Han; XueCheng Bi; QiShan Dai
Journal:  Clin Invest Med       Date:  2008       Impact factor: 0.825

Review 9.  Proliferating cell nuclear antigen: a proteomics view.

Authors:  S N Naryzhny
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  35 in total

1.  Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.

Authors:  Md Faiz Ahmad; Intekhab Alam; Sarah E Huff; John Pink; Sheryl A Flanagan; Donna Shewach; Tessianna A Misko; Nancy L Oleinick; William E Harte; Rajesh Viswanathan; Michael E Harris; Chris Godfrey Dealwis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

Review 2.  Forging Ahead through Darkness: PCNA, Still the Principal Conductor at the Replication Fork.

Authors:  Katherine N Choe; George-Lucian Moldovan
Journal:  Mol Cell       Date:  2017-02-02       Impact factor: 17.970

3.  Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.

Authors:  Sarah E Huff; Faiz Ahmad Mohammed; Mu Yang; Prashansa Agrawal; John Pink; Michael E Harris; Chris G Dealwis; Rajesh Viswanathan
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

4.  Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in ApcMin/+ Mice.

Authors:  Ashish Saxena; Ravinder Tammali; Kota V Ramana; Satish K Srivastava
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

5.  Deviating the level of proliferating cell nuclear antigen in Trypanosoma brucei elicits distinct mechanisms for inhibiting proliferation and cell cycle progression.

Authors:  Ana L Valenciano; Aaron C Ramsey; Zachary B Mackey
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Recognition of a Key Anchor Residue by a Conserved Hydrophobic Pocket Ensures Subunit Interface Integrity in DNA Clamps.

Authors:  Senthil K Perumal; Xiaojun Xu; Chunli Yan; Ivaylo Ivanov; Stephen J Benkovic
Journal:  J Mol Biol       Date:  2019-04-30       Impact factor: 5.469

7.  A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Authors:  Shanna J Smith; Long Gu; Elizabeth A Phipps; Lacey E Dobrolecki; Karla S Mabrey; Pattie Gulley; Kelsey L Dillehay; Zhongyun Dong; Gregg B Fields; Yun-Ru Chen; David Ann; Robert J Hickey; Linda H Malkas
Journal:  Mol Pharmacol       Date:  2014-12-05       Impact factor: 4.436

8.  Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice.

Authors:  Ashish Saxena; Mohammad Shoeb; Ravinder Tammali; Kota V Ramana; Satish K Srivastava
Journal:  Cancer Lett       Date:  2014-09-10       Impact factor: 8.679

9.  A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin.

Authors:  Akira Inoue; Sotaro Kikuchi; Asami Hishiki; Youming Shao; Richard Heath; Benjamin J Evison; Marcelo Actis; Christine E Canman; Hiroshi Hashimoto; Naoaki Fujii
Journal:  J Biol Chem       Date:  2014-01-28       Impact factor: 5.157

10.  The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.

Authors:  Long Gu; Robert Lingeman; Fumiko Yakushijin; Emily Sun; Qi Cui; Jianfei Chao; Weidong Hu; Hongzhi Li; Robert J Hickey; Jeremy M Stark; Yate-Ching Yuan; Yuan Chen; Steven L Vonderfecht; Timothy W Synold; Yanhong Shi; Karen L Reckamp; David Horne; Linda H Malkas
Journal:  Clin Cancer Res       Date:  2018-07-02       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.